Overview
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects
Status:
Completed
Completed
Trial end date:
2003-12-30
2003-12-30
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
This trial is conducted in Japan. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 (NN-X14Mix50) in healthy Japanese subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Novo Nordisk A/STreatments:
Biphasic InsulinsInsulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin, Long-Acting
Criteria
Inclusion Criteria:- BMI (body mass index) between 19-29 kg/m^2 (both inclusive)
- Fasting blood glucose between 3.8-6.0 mmol/L (both inclusive)
- Non-smokers
Exclusion Criteria:
- Subjects with a first-degree relative with diabetes mellitus
- Subjects smoke 5 cigarettes or more per day